Blog
RSS FeedPosted by Michael Wonder on 30 Jun 2022
Zanubrutinib for the treatment of adults with Waldenström’s macroglobulinaemia
29 June 2022 - NICE has published a second appraisal consultation document on the use of zanubrutinib for the treatment ...
Posted by Michael Wonder on 29 Jun 2022
ObsEva announces UK MHRA marketing authorisation for Yselty (linzagolix), an oral GnRH antagonist, for the treatment of uterine fibroids
28 June 2022 - Theramex to commercialise Yselty; ObsEva to receive royalties on commercial sales, as well as development, commercial, and ...
Posted by Michael Wonder on 29 Jun 2022
NICE publishes its 800th technology assessment
29 June 2022 - TAs 799 and 800 are for the same technology. ...
Posted by Michael Wonder on 28 Jun 2022
The Innovative Medicines Fund - good news for patients but has an opportunity been missed to be more ambitious?
27 June 2022 - NHS England and Improvement has announced the launch of the Innovative Medicines Fund. The ABPI’s Director ...
Posted by Michael Wonder on 27 Jun 2022
Positive MHRA decision for Briviact
24 June 2022 - MHRA extends UCB’s therapy for the treatment of partial-onset seizures. ...
Posted by Michael Wonder on 27 Jun 2022
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy
23 June 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 27 Jun 2022
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma
23 June 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 23 Jun 2022
NICE opts to reject Acorda’s MS drug Fampyra
22 June 2022 - NICE has announced its decision to reject Fampyra – also known as fampridine – for use ...
Posted by Michael Wonder on 22 Jun 2022
Slow release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis
21 June 2022 - The Department of Health and Social Care has asked NICE to produce guidance on using slow-release ...
Posted by Michael Wonder on 21 Jun 2022
EQRx announces acceptance of marketing authorisation application by the UK's Medicines and Healthcare Products Regulatory Agency for aumolertinib in EGFR mutated non-small-cell lung cancer
14 June 2022 - Application is based on data from pivotal Phase 3 AENEAS trial in the first-line treatment of EGFR ...
Posted by Michael Wonder on 21 Jun 2022
Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma
21 June 2022 - The Department of Health and Social Care has asked NICE to produce guidance on using tebentafusp ...
Posted by Michael Wonder on 17 Jun 2022
NICE recommends new targeted treatment for early breast cancer
16 June 2022 - NICE has provisionally approved a new treatment for early breast cancer that it says will benefit ...
Posted by Michael Wonder on 16 Jun 2022
NHS lands breakthrough in global battle against superbugs
15 June 2022 - The NHS is set to roll out two ‘superbug’ busting drugs through a world first, pioneering ...
Posted by Michael Wonder on 16 Jun 2022
MHRA joins international partnerships to set global standards for medicines and medical devices regulation
16 June 2022 - These are the International Medical Device Regulatory Forum, the International Council for Harmonisation of Technical Requirements for ...
Posted by Michael Wonder on 16 Jun 2022
Savara awarded innovation passport in United Kingdom for molgramostim nebuliser solution, a novel investigational inhaled biologic
16 June 2022 - Innovation passport awarded to molgramostim for the treatment of auto-immune pulmonary alveolar proteinosis, a rare lung disease. ...